Castle Biosciences, Inc. (CSTL)
NASDAQ: CSTL · Real-Time Price · USD
19.33
+0.17 (0.89%)
Aug 12, 2025, 4:00 PM - Market closed
Endeavor Group Holdings Employees
Castle Biosciences had 761 employees as of December 31, 2024. The number of employees increased by 151 or 24.75% compared to the previous year.
Employees
761
Change (1Y)
151
Growth (1Y)
24.75%
Revenue / Employee
$455,018
Profits / Employee
-$12,439
Market Cap
560.73M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 761 | 151 | 24.75% |
| Dec 31, 2023 | 610 | 67 | 12.34% |
| Dec 31, 2022 | 543 | 198 | 57.39% |
| Dec 31, 2021 | 345 | 144 | 71.64% |
| Dec 31, 2020 | 201 | 66 | 48.89% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
CSTL News
- 8 days ago - Castle Biosciences, Inc. (CSTL) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 8 days ago - Castle Biosciences Reports Second Quarter 2025 Results - GlobeNewsWire
- 14 days ago - Castle Biosciences to Present at the Canaccord Genuity 45th Annual Growth Conference - GlobeNewsWire
- 18 days ago - Castle Biosciences' Founder, President and CEO Derek Maetzold Named a Most Admired CEO by the Houston Business Journal - GlobeNewsWire
- 20 days ago - FDA Grants Breakthrough Device Designation to Castle Biosciences' DecisionDx®-Melanoma Test - GlobeNewsWire
- 26 days ago - Castle Biosciences Honored with Multiple Top Workplaces Awards Recognizing the Company's Strong Culture - GlobeNewsWire
- 4 weeks ago - Castle Biosciences to Release Second Quarter 2025 Financial Results and Host Conference Call on Monday, Aug. 4, 2025 - GlobeNewsWire
- 7 weeks ago - Castle Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire